South San Francisco, CA, Nov. 14, 2024 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutes dedicated to regenerative medicine, marked a historic ...

For details and agenda items please visit our Public Meetings Page.

This past week was muscular dystrophy awareness week, which seems like a short amount of time to focus on such a heartbreaking disease. One in every 3500 boys in the US develops that debilitating and ...

BACKGROUND: The regulation of gene expression is complex and occurs at many levels, including transcriptional and post-transcriptional, in metazoans. Transcriptional regulation is mainly determined by ...

Sponsored by the California Institute for Regenerative Medicine (CIRM) and hosted by Cedars-Sinai, the 7th Annual Alpha Clinics Network Symposium brings together a wide array of stakeholders, ...

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and ...

CIRM has one singular mission: Accelerating world class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. A dedication to ...

Jonathan Thomas, PhD, JD, is President and CEO of the California Institute for Regenerative Medicine (CIRM). Thomas was previously the Chair of the CIRM governing Board from June 2011 to March 2023.

The present project aims at developing a large animal model to test new stem cell therapies for neurological conditions that cause loss of motor neurons. Such conditions include spinal cord injury to ...

Human embryonic stem cells (hESCs) hold great promise for cell therapy as a source of diverse differentiated cell types. One key bottleneck to realizing such potential is allogenic immune rejection of ...

We continue to focus on understanding the role of microRNAs in the development of hematopoietic stem cells from human embryonic stem cells. Progress is slow, but present. We now understand that cells ...

Natural bypass arteries, i.e. collaterals, can improve the prognosis in patients with occlusive artery disease. Unfortunately, some patients never develop identifiable collaterals. However in animal ...